ArticleJournal of virology2017
Antigenic Drift Defines a New D4 Subgenotype of Measles Virus.
Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity.NPJ vaccines · 2025Article
- Neutralizing Antibody Response to Genotypically Diverse Measles Viruses in Clinically Suspected Measles Cases.Viruses · 2023Article
- Pervasive Parental Hesitancy and Resistance towards Measles Rubella Vaccination in Jordan.Vaccines · 2023Article
- Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants.Vaccine · 2022Review
- Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins.Cell reports. Medicine · 2021Article
- Animal and human RNA viruses: genetic variability and ability to overcome vaccines.Archives of microbiology · 2021Review
- MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.PLoS pathogens · 2021Article
- Laboratory methods supporting measles surveillance in Queensland, Australia, 2010-2017.Access microbiology · 2020Article
- Article
- Measles, the need for a paradigm shift.European journal of epidemiology · 2019Review
- Article
- Bornaviruses in naturally infectedInfection ecology & epidemiology · 2019Article
- Article
- Hemagglutinin-specific neutralization of subacute sclerosing panencephalitis viruses.PloS one · 2018Article
- Complete Genomic Sequence of Canine Distemper Virus from an Ethiopian Wolf.Genome announcements · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The measles virus hemagglutinin (MeV-H) protein is the main target of protective neutralizing antibodies. Using a panel of monoclonal antibodies (MAbs) that recognize known major antigenic sites in MeV-H, we identified a D4 genotype variant that escapes neutralization by MAbs targeting the neutralizing epitope (NE) antigenic site. By site-directed mutagenesis, L249P was identified as the critical mutation disrupting the NE in this genotype D4 variant. Forty-two available D4 genotype gene sequences were subsequently analyzed and divided into 2 groups according to the presence or absence of the L249P MeV-H mutation. Further analysis of the MeV-N gene sequences of these 2 groups confirmed that they represent clearly definable, sequence-divergent D4 subgenotypes, which we named subgenotypes D4.1 and D4.2. The subgenotype D4.1 MeVs were isolated predominantly in Kenya and Ethiopia, whereas the MAb-resistant subgenotype D4.2 MeVs were isolated predominantly in France and Great Britain, countries with higher vaccine coverage rates. Interestingly, D4.2 subgenotype viruses showed a trend toward diminished susceptibility to neutralization by human sera pooled from approximately 60 to 80 North American donors. Escape from MAb neutralization may be a powerful epidemiological surveillance tool to monitor the evolution of new MeV subgenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.